Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Join us in Paris from 4 to 6 October at the leading congress in precision oncology and translational research, a high-level event exploring totally new concepts in the field of translational research.
A platform to explore, discuss and collaborate on the latest advancements that will shape the future of the breast cancer field
Submit your abstract, or trial in progress abstract in all phases of clinical research, by 9 January 2024.
Online application is open until 26 September 2023
Online application is now open until 24 October 2023
This one-of-a-kind event gathers the international and Asia-Pacific oncology community to share the latest advancements in the field and find new opportunities for collaboration.
Prof. Fabrice André, ESMO President-Elect 2023-2024, explains the main advantages of submitting your abstract to the ESMO Virtual Plenaries
The latest developments on immune modulation, including tumour microenvironment, immunometabolism and more!
Shape the future of cancer drug development and take part in this unique forum gathering all the relevant stakeholders in oncology
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Findings from the NAPOLI 3 study
ESMO welcomes the 2023 UN Political Declaration on Universal Health Coverage (UHC) as it represents an extraordinary opportunity to accelerate action on cancer prevention and control globally.
Findings from the phase II study
Findings from a meta-analysis
Further action needed to ensure patients with cancer are not left behind
This updated EANO–ESMO Clinical Practice Guideline on leptomeningeal metastasis from solid tumours covers clinical, imaging and cytological diagnosis, staging and risk assessment, treatment and follow-up. A treatment and management algorithm is provided.
Findings from a phase II study
Findings from the TROPiCS-02 study
Evidence for efficacy is based on results from the MonumenTAL-1 study
Findings from the NAPOLI 3 study
Findings from the phase II study
Findings from a meta-analysis
Findings from a phase II study
Findings from the TROPiCS-02 study
Evidence for efficacy is based on results from the MonumenTAL-1 study
It is a generic of Firmagon which has been authorised in the EU since 2009
Findings from the first study to report on HER2-low expression across multiple solid tumour types
The new online tool comes in an interactive, concise, and updatable visual format to support practicing oncologists in the rapidly evolving medical field
The ESMO Breast Cancer Congress 2023, will be held onsite in Berlin, Germany, and online, through a virtual platform, between 11-13 May 2023
Adding immunotherapy to standard chemotherapy for first-line treatment of advanced or first recurrence of endometrial cancer significantly improves progression-free survival (PFS) compared to chemotherapy alone, with a promising early indication of improved overall survival (OS)
ESMO is pleased to announce a combination of brand-new and well-established events happening in March, tackling two specific areas of oncology, with leading experts discussing novel clinical data and the latest treatment options
A total of 1,261,990 people will die from cancer in 2023 in the EU (EU-27). A further 172,314 people will die from the disease in the UK, according to new research published in the leading cancer journal Annals of Oncology today
The ESMO Targeted Anticancer Therapies Congress 2023, the gathering focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development, will be held in Paris, France, on 6-8 March 2023.
The ESMO Gynaecological Cancers Congress 2023, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide an overview of the latest treatments as well as insights into the biology and biomarkers of ovarian, uterine, cervical and even rare gynaecological cancers.
The European Society for Medical Oncology (ESMO) has developed a quality of life (QoL) checklist that is now integral to the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) - a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
The ESMO Immuno-Oncology Congress 2022, an annual congress dedicated to the presentation and discussion of the latest scientific developments in this fast-moving field, will be held in person in Geneva, Switzerland, and virtually between 7-9 December.
Committed to delivering high-quality medical science and to helping the oncology community to stay up to date with the latest developments in the field, ESMO has expanded its portfolio of journals.
ESMO has announced today the winners of the 2023 ESMO Society Awards.
According to the 2023 Journal Citation Reports, the Impact Factor (IF) of ESMO Journals remains strong this year
The introduction of a specially validated version of the ESMO-MCBS (European Society for Medical Oncology-Magnitude of Clinical Benefit Scale) for heamatological malignancies, developed in collaboration with the European Hematology Association (EHA), represents a milestone in the development of value assessment in oncology
ESMO launched the ESMO Living Guidelines, a new tool designed to make the ESMO Clinical Practice Guidelines (CPGs) easier to use in oncologists’ routine clinical practice and support optimal decision-making in a rapidly evolving medical field
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
The European Society for Medical Oncology (ESMO) has announced today that the 2023 ESMO Breast Cancer Award is bestowed to Sara A. Hurvitz for her remarkable contributions to breast cancer clinical and laboratory-based research
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) have announced today that the 2023 Heine H. Hansen Award is conferred on Paul Baas for his outstanding contribution to thoracic oncology research
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
This summer, photos of New York covered by smoke spread widely catching global attention on the massive wildfires in Canadian forests that caused that apocalyptic scenario. But why should we as oncologists be concerned about such events?
Molecular characterisation of tumour subtypes and immunotherapy are key areas attracting researchers’ efforts that may shape the future of clinical practice, according to ESMO President Prof. Andrés Cervantes
Teresa Del Giudice is the 30,000th ESMO Member. In this interview she explains what motivated her to join the community.
Recent findings from studies confirm the promises of ctDNA in this setting, but unanswered questions still remain about timing and methodology
An ESMO study shows that precision oncology is out of reach for the majority of patients, with costs of technologies and reimbursement policies acting as major barriers
Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
From the 2023 World Conference on Lung Cancer:
Latest findings from the AEGEAN trial indicate NSCLC surgical outcomes are not affected by perioperative durvalumab but that patients with an EGFR mutation do not benefit
From the 2023 World Conference on Lung Cancer:
Patients with ROS1 fusion-positive non-small-cell lung cancer show ongoing responses to repotrectinib when given as first- or second-line ROS1 tyrosine kinase inhibitor therapy
From the 2023 World Conference on Lung Cancer:
The addition of platinum-based chemotherapy to first-line osimertinib improves progression-free survival for patients with advanced, EGFR-mutated non-small-cell lung cancer
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Switzerland
Spain
France
Switzerland
Spain
France
Switzerland
Portugal
Republic of Singapore
Republic of Singapore
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Members: the main session of the ESMO Examination 2023 will be held on Saturday 21 October during the ESMO Congress 2023.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
